Literature DB >> 15718848

Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.

Ferdinand Wnm Wit1, Daniel H Blanckenberg, Kees Brinkman, Jan M Prins, Marchina E van der Ende, Margriet Me Schneider, Jan-Willem Mulder, Frank de Wolf, Joep Ma Lange.   

Abstract

We studied the dynamics of CD4 cell counts after the interruption of virologically successful highly active antiretroviral therapy (HAART) in 139 patients. Changes in CD4 cell counts during HAART interruption followed a biphasic pattern: an initial rapid decline during the first month followed by a slow decrease. During 48 weeks of follow-up mean CD4 cell counts remained just above the mean pre-HAART level. This limits the feasibility of structured treatment interruptions for patients with low nadir CD4 cell counts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718848

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

Review 1.  Measuring the latent reservoir in vivo.

Authors:  Marta Massanella; Douglas D Richman
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

2.  The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model.

Authors:  Parastu Kasaie; Jeff Pennington; Maunank S Shah; Stephen A Berry; Danielle German; Colin P Flynn; Chris Beyrer; David W Dowdy
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

3.  A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads.

Authors:  Kelly A Metcalf Pate; Christopher W Pohlmeyer; Victoria E Walker-Sperling; Jeremy B Foote; Kevin M Najarro; Catherine G Cryer; Maria Salgado; Lucio Gama; Elizabeth L Engle; Erin N Shirk; Suzanne E Queen; Stanley Chioma; Meghan S Vermillion; Brandon Bullock; Ming Li; Claire E Lyons; Robert J Adams; M Christine Zink; Janice E Clements; Joseph L Mankowski; Joel N Blankson
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

4.  Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.

Authors:  Sarah Fidler; Ashley D Olson; Heiner C Bucher; Julie Fox; John Thornhill; Charles Morrison; Roberto Muga; Andrew Phillips; John Frater; Kholoud Porter
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

5.  Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study.

Authors:  Parastu Kasaie; Christina M Schumacher; Jacky M Jennings; Stephen A Berry; Susan A Tuddenham; Maunank S Shah; Eli S Rosenberg; Karen W Hoover; Thomas L Gift; Harrell Chesson; Danielle German; David W Dowdy
Journal:  BMJ Open       Date:  2019-03-04       Impact factor: 2.692

6.  Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Authors:  Jürgen K Rockstroh; David Asmuth; Giuseppe Pantaleo; Bonaventura Clotet; Daniel Podzamczer; Jan van Lunzen; Keikawus Arastéh; Ronald Mitsuyasu; Barry Peters; Nozza Silvia; Darren Jolliffe; Mats Ökvist; Kim Krogsgaard; Maja A Sommerfelt
Journal:  PLoS One       Date:  2019-01-30       Impact factor: 3.240

7.  Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.

Authors:  Britta L Jewell; Edinah Mudimu; John Stover; Debra Ten Brink; Andrew N Phillips; Jennifer A Smith; Rowan Martin-Hughes; Yu Teng; Robert Glaubius; Severin Guy Mahiane; Loveleen Bansi-Matharu; Isaac Taramusi; Newton Chagoma; Michelle Morrison; Meg Doherty; Kimberly Marsh; Anna Bershteyn; Timothy B Hallett; Sherrie L Kelly
Journal:  Lancet HIV       Date:  2020-08-06       Impact factor: 12.767

8.  Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Authors:  Elizabeth Hamlyn; Fiona M Ewings; Kholoud Porter; David A Cooper; Giuseppe Tambussi; Mauro Schechter; Court Pedersen; Jason F Okulicz; Myra McClure; Abdel Babiker; Jonathan Weber; Sarah Fidler
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.